Cleared Traditional

K220265 - ADVIA Centaur® NT-proBNPII (PBNPII) (FDA 510(k) Clearance)

Class II Chemistry device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K220265 · Siemens Healthcare Diagnostics, Inc. · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 2023
Decision
601d
Days
Class 2
Risk

K220265 is an FDA 510(k) clearance for the ADVIA Centaur® NT-proBNPII (PBNPII). Classified as Test, Natriuretic Peptide (product code NBC), Class II - Special Controls.

Submitted by Siemens Healthcare Diagnostics, Inc. (Tarrytown, US). The FDA issued a Cleared decision on September 24, 2023 after a review of 601 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1117 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Chemistry submissions.

View all Siemens Healthcare Diagnostics, Inc. devices

Submission Details

510(k) Number K220265 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 31, 2022
Decision Date September 24, 2023
Days to Decision 601 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
513d slower than avg
Panel avg: 88d · This submission: 601d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code NBC Test, Natriuretic Peptide
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1117
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - NBC Test, Natriuretic Peptide

All 44
Devices cleared under the same product code (NBC) and FDA review panel - the closest regulatory comparables to K220265.
Access BNP II
K252169 · Beckman Coulter, Inc. · Mar 2026
Alere NT-proBNP for Alinity i
K253539 · Axis-Shield Diagnostics, Ltd. · Feb 2026
Alere NT-proBNP for Alinity i Reagent Kit
K241176 · Axis-Shield Diagnostics, Ltd. · Jan 2025
Access NT-proBNP
K232164 · Beckman Coulter, Inc. · Apr 2024
Elecsys proBNP II, Elecsys proBNP II STAT
K223637 · Roche Diagnostics · Jul 2023
Elecsys proBNP II, Elecsys proBNP II STAT
K210546 · Roche Diagnostics · Mar 2022